News Releases :: Sutro Biopharma, Inc. (STRO)

Jul 9, 2024 8:00 am EDT

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

May 13, 2024 4:30 pm EDT

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Apr 30, 2024 8:00 am EDT

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 2, 2024 6:18 am EDT

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024 1:00 am EDT

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024 4:30 pm EDT

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Feb 6, 2024 4:05 pm EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

Jan 4, 2024 4:05 pm EST

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 14, 2023 4:05 pm EST

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Dec 11, 2023 4:05 pm EST

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023